Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Accumulated Expenses (2020 - 2025)

Inmune Bio (INMB) has disclosed Other Accumulated Expenses for 6 consecutive years, with $511000.0 as the latest value for Q2 2025.

  • Quarterly Other Accumulated Expenses fell 1.92% to $511000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $511000.0 through Jun 2025, down 1.92% year-over-year, with the annual reading at $517000.0 for FY2024, 5.73% up from the prior year.
  • Other Accumulated Expenses hit $511000.0 in Q2 2025 for Inmune Bio, up from $480000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $778000.0 in Q3 2022 to a low of $474000.0 in Q4 2021.
  • Historically, Other Accumulated Expenses has averaged $548722.2 across 5 years, with a median of $531000.0 in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 149.47% in 2021 and later tumbled 36.25% in 2023.
  • Year by year, Other Accumulated Expenses stood at $474000.0 in 2021, then increased by 29.96% to $616000.0 in 2022, then decreased by 20.62% to $489000.0 in 2023, then increased by 5.73% to $517000.0 in 2024, then decreased by 1.16% to $511000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for INMB at $511000.0 in Q2 2025, $480000.0 in Q1 2025, and $517000.0 in Q4 2024.